Treatment with TNF-α inhibitors have been reported to increase reactivation of concurrent chronic hepatitis B and potentially increase hepatitis C virus (HCV) replication7, further supporting the importance of TNF-α in defending the human body against viral infections. Here, TNF is linked to chronic hepatitis B virus infection.